TG Therapeutics
TG Therapeutics Inc is a commercial-stage biopharmaceutical enterprise headquartered in New York City, New York. The company focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its primary commercial product is ublituximab, a targeted monoclonal antibody therapy approved for treating multiple sclerosis and related conditions. Principal revenue is derived from direct commercial product sales of its approved pharmaceutical therapeutics. The enterprise serves clinical physicians, specialty treatment centers, and healthcare patients across North America. TG Therapeutics Inc is publicly traded on the Nasdaq Stock Market.
7 of the funds FundTelligence covers report a position in TG Therapeutics.
- Legal name
- TG Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding TG Therapeutics
- DNB Fund Women's Health — DNB · 4.48 % (full portfolio disclosed, August 2026)
- DNB Bioteknologi — DNB · 2.33 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.81 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.11 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.1 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.08 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)